Ocular Surgery In Infants And Post-Op Eye Drop Risks Overview This clinical observational cohort study delves into the prevalence and risk factors associated with hypothalamus-pituitary-adrenal (HPA) axis suppression in infants subjected to glucocorticoid (GC) eye drops subsequent to ocular surgery, focusing on cataract and glaucoma procedures. The research aims to discern the
Health Topics
Cancer Care: Gender Bias In Decision-Making
Cancer Care: Gender Bias In Decision-Making Overview In the realm of cancer care, the integration and execution of shared decision-making within clinical practice guidelines (CPGs) and consensus statements could potentially exhibit gender-based disparities. This study aimed to meticulously analyze recommendations pertaining to shared decision-making within CPGs and consensus statements, specifically focusing on
Respiratory Syncytial Virus Infection: A Tool For Assessing Clinical Severity
Respiratory Syncytial Virus Infection: A Tool For Assessing Clinical Severity Respiratory syncytial virus (RSV) is a major cause of acute respiratory tract infection (ARTI) and the primary reason for hospitalization among infants, leading to substantial health and socioeconomic challenges. Ranging from mild cold-like symptoms to severe lower respiratory tract infection (LRTI),
Gynecologic Cancer Survivors: A Study Of Lifestyle Factors
Gynecologic Cancer Survivors: A Study Of Lifestyle Factors Overview Promoting positive outcomes for gynecologic cancer survivors hinges on upholding a healthy lifestyle. We scrutinized behaviors among gynecologic cancer survivors (n = 1824) and non-cancer individuals via cross-sectional analysis, using 2020 Behavioral Risk Factor Surveillance System data. Colorectal cancer screening rates were 7.9%
Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk
Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk The number of non-Hodgkin lymphoma (NHL) cases is rising, with an estimated 81,560 new diagnoses in the US in 2021. As survival rates improve, more NHL survivors face potential late effects, including secondary malignancies (SM) linked to treatments like chemotherapy and radiation. This research revisits
Antithyroid Drug Therapy And Cardiovascular Morbidity
Antithyroid Drug Therapy And Cardiovascular Morbidity Overview The impact of thyroid function test (TFT) variability and its link to adverse health outcomes in antithyroid drug (ATD) therapy remains an unexplored area. This study aimed to investigate the relationship between TFT variability and cardiovascular morbidity during ATD therapy. Conducted at Tampere University Hospital,
Off-label Medication Use In Oncology
Off-label Medication Use In Oncology Cancer Research and Medicinal Drugs Cancer research and innovation are highly active, resulting in the introduction of new medications into the therapeutic arsenal. However, incorporating these new drugs into clinical practice is a challenging and time-consuming process due to regulatory requirements. Before a drug can be marketed and
Bedside Pediatric Early Warning System: A Validation Study
Bedside Pediatric Early Warning System: A Validation Study Overview Conducted in an 80-bed pediatric oncology specialty hospital in the Netherlands, this research was initiated to evaluate the predictive utility of the adapted Bedside Pediatric Early Warning System (BedsidePEWS) score. This study aimed to explore the correlation of this score with unanticipated transfers
Chronic Hyponatremia in Acute Heart Failure
Chronic Hyponatremia in Acute Heart Failure Overview This study aimed to comprehensively assess hyponatremia in patients with acute heart failure (AHF), focusing on its prevalence, associations, hospital course, and post-discharge outcomes. The research analyzed a cohort of 8,298 AHF patients from the European Society of Cardiology Heart Failure Long-Term Registry, regardless of
Eyelid Rhabdomyosarcoma Survival In Children’s Oncology
Eyelid Rhabdomyosarcoma Survival In Children's Oncology Overview Survival outcomes in Orbital Rhabdomyosarcoma (ORMS) typically show excellent results, especially in low-risk cases (stage 1, group I-III, embryonal RMS). However, long-term follow-up data on low-risk ORMS and less common subgroups treated in recent Children's Oncology Group (COG) trials were previously unreported. To fill this
